Newsfeeds - Spark Newswire

1 minute read

News

Kala Pharmaceuticals Granted U.S. Patent #11,369,611 Therapeutic compounds and uses thereof

Today, 1:00 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6733&f=G&l=50&d=PTXT&p=135&S1=20220628&OS=20220628&RS=20220628

KALA

4 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 1:00 PM

During Friday's session, 59 stocks hit new 52-week lows.

ACB

7 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 1:00 PM

On Thursday, 94 companies set new 52-week lows.

ACOR

6 minute read

88 Biggest Movers From Yesterday

By Lisa Levin

Today, 1:00 PM

Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw Companies.

ADXN

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 1:00 PM

AEMD

2 minute read

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 1:00 PM

BIMI

1 minute read

This Biopharma Stock Surges After Offloading Its Ophthalmic Eye Drop Portfolio

By Vandana Singh

Today, 1:00 PM

Alcon AG (NYSE:ALC) has agreed to acquire Eysuvis (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals Inc (NASDAQ:KALA). Eysuvis will complement…

ALC

2 minute read

Kala Announced Entry into Definitive Agreement to Sell EYSUVIS and INVELTYS to Alcon Inc for $60M Upfront Plus Potential Milestones

By Charles Gross

Today, 1:00 PM

Kala Pharmaceuticals, Inc.

KALA

1 minute read

Analyst Ratings

What 4 Analyst Ratings Have To Say About Kala Pharmaceuticals

By Benzinga Insights

Today, 1:00 PM

Kala Pharmaceuticals (NASDAQ:KALA) has observed the following analyst ratings within the last quarter:

KALA

3 minute read

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More

By Shanthi Rexaline

Today, 1:00 PM

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.

ATNX